UPLIZNA® (inebilizumab) is the first and only targeted CD19+ B-cell-depleting monotherapy proven to reduce attacks in adult AQP4-IgG+ neuromyelitis optica spectrum disorder (NMOSD) patients.1-4

Learn More

UPLIZNA is indicated as monotherapy for the treatment of adult patients with NMOSD who are anti-aquaporin‑4 immunoglobulin G (AQP4-IgG) seropositive.1

Treatment checklist icon.Treatment-checklist-icon. Treatment checklist icon.Treatment-checklist-icon. Treatment checklist icon.Treatment-checklist-icon.

Support & Resources

Pre- and during-UPLIZNA treatment information

What you need to know

e-services-icon e-services-icon e-services-icon

Scientific e-Service

Stay up-to-date on UPLIZNA with the latest scientific news, updates, and materials on treating NMOSD

Sign up now

Summary of Product Characteristics

  1. UPLIZNA Summary of Product Characteristics.
  2. Horizon Therapeutics plc receives European Commission (EC) approval of UPLIZNA® (inebilizumab) for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD). News release. Horizon Therapeutics plc. May 2, 2022. Accessed May 4, 2022. https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-receives-european-commission-ec
  3. ENSPRYNG Summary of Product Characteristics.
  4. SOLIRIS Summary of Product Characteristics.